Coherus Oncology, Inc. (CHRS)
Automate Your Wheel Strategy on CHRS
With Tiblio's Option Bot, you can configure your own wheel strategy including CHRS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol CHRS
- Rev/Share 0.719
- Book/Share 0.7552
- PB 1.5361
- Debt/Equity 0.0222
- CurrentRatio 1.2381
- ROIC -1.1717
- MktCap 134459298.0
- FreeCF/Share -0.776
- PFCF -1.4909
- PE 0.87
- Debt/Assets 0.0038
- DivYield 0
- ROE -5.7472
- Rating A+
- Score 4
- Recommendation Buy
- P/E Score 3
- DCF Score 5
- P/B Score 3
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | CHRS | Maxim Group | Hold | Buy | -- | -- | Sept. 4, 2025 |
| Downgrade | CHRS | UBS | Buy | Neutral | $4 | $1.5 | Aug. 16, 2024 |
News
Coherus Oncology Presents at SITC Clinical Multiomic Biomarker Data for CHS-114, a Highly Selective anti-CCR8 Cytolytic Antibody
Published: November 07, 2025 by: GlobeNewsWire
Sentiment: Neutral
– CHS-114 demonstrated robust and selective depletion of CCR8+ Tregs as well as favorable immune remodeling in tumor tissue from head and neck squamous cell carcinoma (HNSCC) patients –
Read More
Arvind Sood joins Coherus Oncology as Chief Strategy and Corporate Affairs Officer
Published: November 06, 2025 by: GlobeNewsWire
Sentiment: Neutral
– Responsible for Corporate Development, Investor Relations, Government Affairs – REDWOOD CITY, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS), today announced that Arvind Sood has joined the Company as Chief Strategy and Corporate Affairs Officer reporting to Denny Lanfear, Chairman and Chief Executive Officer.
Read More
Coherus Oncology Announces Poster Presentation at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
Published: October 03, 2025 by: GlobeNewsWire
Sentiment: Neutral
– CHS-114, an anti-CCR8 cytolytic antibody, will also be featured in SITC's upcoming webinar series “Targets for Cancer IO: A Deep Dive” on October 22, 2025 – – CHS-114, an anti-CCR8 cytolytic antibody, will also be featured in SITC's upcoming webinar series “Targets for Cancer IO: A Deep Dive” on October 22, 2025 –
Read More
Coherus Oncology: Five Readouts Or More Possible In 2026
Published: October 01, 2025 by: Seeking Alpha
Sentiment: Neutral
Coherus Oncology's Loqtorzi has resumed growth in earnest, with Q2 2025 net revenues of $10M. The company could report readouts from its drugs in three indications in H1 2026: casdozokitug in hepatocellular carcinoma, CHS-114 in gastric cancer, and CHS-114 in head and neck cancer. There could be further readouts from CHS-114 in 2026 in esophageal squamous cell carcinoma and colorectal cancer.
Read More
About Coherus Oncology, Inc. (CHRS)
- IPO Date 2014-11-06
- Website https://www.coherus.com
- Industry Biotechnology
- CEO Dennis M. Lanfear
- Employees 228